Vascular Health and Risk Management, 1178-2048

Journal

More filtering options
  1. 2019
  2. Prospective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: Cross-sectional evaluation of coronary flow reserve

    Inger Haraldsson, Li Ming Gan, Sara Svedlund, Kristina Torngren, Helena U. Westergren, Björn Redfors, Maria Lagerström-Fermér, Oskar Angerås, Truls Råmunddal, Petur Petursson, Jacob Odenstedt, Per Albertsson, David Erlinge & Elmir Omerovic, 2019, In : Vascular Health and Risk Management. 15, p. 375-384

    Research output: Contribution to journalArticle

  3. 2014
  4. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.

    Sylvia Haas, Christoph Bode, Bo Norrving & Alexander Gg Turpie, 2014, In : Vascular Health and Risk Management. 10, Mar 10, p. 101-114

    Research output: Contribution to journalReview article

  5. 2013
  6. 2010
  7. 2009
  8. 2008
  9. Cardiovascular co-morbidity in rheumatic diseases.

    Carl Turesson, Lennart Jacobsson & Eric L Matteson, 2008, In : Vascular Health and Risk Management. 4, 3, p. 605-614

    Research output: Contribution to journalReview article

  10. Cigarette smoking leads to reduced relaxant responses of the cutaneous microcirculation.

    MarieLouise Edvinsson, Sven Andersson, Cang-Bao Xu & Lars Edvinsson, 2008, In : Vascular Health and Risk Management. 4, 3, p. 699-704

    Research output: Contribution to journalArticle

  11. Early vascular aging (EVA): consequences and prevention.

    Peter Nilsson, 2008, In : Vascular Health and Risk Management. 4, 3, p. 547-552

    Research output: Contribution to journalReview article

  12. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.

    Bo Ahrén, 2008, In : Vascular Health and Risk Management. 4, 2, p. 383-394

    Research output: Contribution to journalArticle

  13. Postpartum thromboembolism: severe events might be preventable using a new risk score model.

    Pelle Lindqvist, Jelena Torsson, Asa Almqvist & Ola Björgell, 2008, In : Vascular Health and Risk Management. 4, 5, p. 1081-1087

    Research output: Contribution to journalArticle

  14. 2007
  15. A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

    Mozhgan Dorkhan & Anders Frid, 2007, In : Vascular Health and Risk Management. 3, 5, p. 721-731

    Research output: Contribution to journalReview article

  16. Comprehensive cardiovascular risk management--what does it mean in practice?

    Leif RW Erhardt, Robert Moller & Juan García Puig, 2007, In : Vascular Health and Risk Management. 3, 5, p. 587-603

    Research output: Contribution to journalReview article

  17. Rationale for multiple risk intervention: the need to move from theory to practice.

    Leif RW Erhardt, 2007, In : Vascular Health and Risk Management. 3, 6, p. 985-997

    Research output: Contribution to journalArticle